Significantly Reduces Stroke-Induced Disability: Latest Clinical Results of Simcere's Investigational New Drug Published

On October 24, Simcere announced that a Chinese multicenter, randomized, double-blind, placebo-controlled new stroke drug study, TASTE-2, led by Professor Wang Yongjun from Beijing Tiantan Hospital, was presented as an oral report at the World Stroke Congress (WSC). The study showed that in patients with acute ischemic stroke, the application of Edaravone Dexborneol for cerebral cell protection prior to endovascular thrombectomy (EVT) significantly improved the proportion of patients achieving neurological independence at 90 days. The publication of these results is expected to support Edaravone Dexborneol as a combination therapy for stroke thrombectomy, applied before the procedure to enhance post-stroke functional recovery outcomes.

The oral presentation at this World Stroke Conference showed that in the TASTE-2 study, among 1,362 patients with moderate to severe stroke who underwent thrombectomy, the use of Edaravone Dexborneol Injection Concentrate prior to the procedure resulted in 55.0% of patients achieving a functional score of 2 or less at 90 days, compared to 49.6% in the placebo group—a difference that was statistically significant. The safety profile was also favorable. This indicates that providing neuroprotection before reperfusion therapy in stroke can further enhance treatment outcomes and reduce disability.

"The King of Cancers" Achieves Over 90% Overall Survival Rate! Clinical Trial Results of Small Molecules Targeting Multiple KRAS Mutations Shine

Revolution Medicines announced on October 4 that its investigational pan-RAS inhibitor RMC-6236 demonstrated encouraging anti-tumor activity and safety in previously treated pancreatic ductal adenocarcinoma (PDAC) patients. Analysis showed that RMC-6236 monotherapy as a second-line treatment improved median progression-free survival (PFS) and overall survival (OS) in PDAC patients with any RAS mutation, with a 6-month overall survival rate as high as 91%. The phase 3 clinical trial of this therapy, RASolute 302, is currently underway.

RMC-6236-001 is a Phase 1/1b multicenter, open-label, dose-escalation and dose-expansion study designed to evaluate the efficacy of RMC-6236 as a monotherapy for patients with advanced solid tumors carrying RAS mutations or wild-type RAS. As of July 23, 2024, a total of 127 PDAC patients have received RMC-6236 treatment, with doses ranging from 160 mg to 300 mg daily.

Effective within 30 minutes, lasting 10 hours! Presbyopia eye drops有望在明年获FDA批准

LENZ Therapeutics Announces FDA Acceptance of NDA for LNZ100 (1.75% Aceclidine) Ophthalmic Solution for Presbyopia Treatment

Most of the current drug therapies for presbyopia under development adopt the strategy of pupil constriction. The pinhole effect generated by pupil constriction can increase the depth of field, allowing light passing through the pupil to focus on the retina.

This NDA submission is primarily supported by positive data from the pivotal Phase 3 CLARITY trial. CLARITY is a Phase 3 multicenter, double-blind, randomized study evaluating the efficacy and safety of LNZ100 and LNZ101 in treating presbyopia. It consists of two six-week efficacy trials, CLARITY 1 and 2, and a six-month safety trial, CLARITY 3.